Your browser doesn't support javascript.
loading
Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report.
St Laurent, Jessica D; Abel, Mary Kathryn; Liu, Joyce; Quade, Bradley J; Davis, Michelle R.
Affiliation
  • St Laurent JD; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
  • Abel MK; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
  • Liu J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA, USA.
  • Quade BJ; Division of Women's and Perinatal Pathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Davis MR; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
Gynecol Oncol Rep ; 51: 101322, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38273934
ABSTRACT
•Ovarian carcinosarcoma is a rare ovarian cancer histology that has limited treatment options.•In this study, we present an unusual association between carcinosarcoma and a STIC lesion.•In select patients with carcinosarcoma, PARP inhibition may provide clinical benefit.
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Gynecol Oncol Rep Year: 2024 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Gynecol Oncol Rep Year: 2024 Type: Article Affiliation country: United States